A semi-quantitative assessment of CD73 expression on stromal cells (Histological score (H-score): % of positive stromal cells × staining intensity) showed a higher expression of CD73 in arm B (without oleclumab) mainly driven by CD73 expression in the stroma of primary tumors from patients with de novo metastatic disease (Supplementary Table 8). This evidence concerns the gene NT5E and metastatic neoplasm.